Articles producció científica> Ciències Mèdiques Bàsiques

Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response

  • Identification data

    Identifier: imarina:9291936
    Handle: http://hdl.handle.net/20.500.11797/imarina9291936
  • Authors:

    Lejeune M
    Reverté L
    Sauras E
    Gallardo N
    Bosch R
    Roso A
    Petit A
    Peg V
    Riu F
    García-Fontgivell J
    Ibáñez J
    Relea F
    Vieites B
    Bor C
    de la Cruz-Merino L
    Arenas M
    Rodriguez V
    Galera J
    Korzynska A
    Belhomme P
    Plancoulaine B
    Álvaro T
    López C
  • Others:

    Author, as appears in the article.: Lejeune M; Reverté L; Sauras E; Gallardo N; Bosch R; Roso A; Petit A; Peg V; Riu F; García-Fontgivell J; Ibáñez J; Relea F; Vieites B; Bor C; de la Cruz-Merino L; Arenas M; Rodriguez V; Galera J; Korzynska A; Belhomme P; Plancoulaine B; Álvaro T; López C
    Department: Ciències Mèdiques Bàsiques
    URV's Author/s: Arenas Prat, Meritxell / Bosch Princep, Ramon / Galera Ortega, Juana / Lejeune, Marylène Marie / Sauras Colón, Esther
    Keywords: Tumor microenvironment Triple-negative breast cancer Survival Relapse Neoadjuvant therapy Infiltrating lymphocytes Immune markers Genetic markers tumor microenvironment survival standard signature risk relapse neoadjuvant therapy immune markers identification genetic markers
    Abstract: With a high risk of relapse and death, and a poor or absent response to therapeutics, the triple-negative breast cancer (TNBC) subtype is particularly challenging, especially in patients who cannot achieve a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). Although the tumor microenvironment (TME) is known to influence disease progression and the effectiveness of therapeutics, its predictive and prognostic potential remains uncertain. This work aimed to define the residual TME profile after NAC of a retrospective cohort with 96 TNBC patients by immunohistochemical staining (cell markers) and chromogenic in situ hybridization (genetic markers). Kaplan–Meier curves were used to estimate the influence of the selected TME markers on five-year overall survival (OS) and relapse-free survival (RFS) probabilities. The risks of each variable being associated with relapse and death were determined through univariate and multivariate Cox analyses. We describe a unique tumor-infiltrating immune profile with high levels of lymphocytes (CD4, FOXP3) and dendritic cells (CD21, CD1a and CD83) that are valuable prognostic factors in post-NAC TNBC patients. Our study also demonstrates the value of considering not only cellular but also genetic TME markers such as MUC-1 and CXCL13 in routine clinical diagnosis to refine prognosis modelling.
    Thematic Areas: Oncology Medicina iii Cancer research
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: juana.galera@urv.cat marylenemarie.lejeune@urv.cat meritxell.arenas@urv.cat esther.sauras@estudiants.urv.cat
    Author identifier: 0000-0001-8441-9404 0000-0003-0815-2570
    Record's date: 2023-06-09
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.mdpi.com/2072-6694/15/3/597
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Cancers. 15 (3):
    APA: Lejeune M; Reverté L; Sauras E; Gallardo N; Bosch R; Roso A; Petit A; Peg V; Riu F; García-Fontgivell J; Ibáñez J; Relea F; Vieites B; Bor C; de la Cr (2023). Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response. Cancers, 15(3), -. DOI: 10.3390/cancers15030597
    Article's DOI: 10.3390/cancers15030597
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2023
    Publication Type: Journal Publications
  • Keywords:

    Cancer Research,Oncology
    Tumor microenvironment
    Triple-negative breast cancer
    Survival
    Relapse
    Neoadjuvant therapy
    Infiltrating lymphocytes
    Immune markers
    Genetic markers
    tumor microenvironment
    survival
    standard
    signature
    risk
    relapse
    neoadjuvant therapy
    immune markers
    identification
    genetic markers
    Oncology
    Medicina iii
    Cancer research
  • Documents:

  • Cerca a google

    Search to google scholar